Patents by Inventor Hiroji Uemura

Hiroji Uemura has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Method for detecting castration-resistant prostate cancer and detection reagent
    Patent number: 11604194
    Abstract: The present invention aims to provide a method for simply and highly accurately detecting castration-resistant prostate cancer (CRPC), and a reagent that can be used for this method. By measuring the level of GDF15 propeptide present in a sample as a novel detection marker for CRPC, acquisition of castration resistance in a prostate cancer patient during or after endocrine therapy is detected. An antibody that specifically recognizes GDF15 propeptide is included in the CRPC detection reagent.
    Type: Grant
    Filed: February 23, 2017
    Date of Patent: March 14, 2023
    Assignees: PUBLIC UNIVERSITY CORPORATION YOKOHAMA CITY UNIVERSITY, TOSOH CORPORATION
    Inventors: Noriaki Arakawa, Hisashi Hirano, Hiroji Uemura, Yusuke Ito, Shohei Myoba, Norihisa Ohtake
  • METHOD FOR DETECTING CASTRATION-RESISTANT PROSTATE CANCER AND DETECTION REAGENT
    Publication number: 20210190786
    Abstract: The present invention aims to provide a method for simply and highly accurately detecting castration-resistant prostate cancer (CRPC), and a reagent that can be used for this method. By measuring the level of GDF15 propeptide present in a sample as a novel detection marker for CRPC, acquisition of castration resistance in a prostate cancer patient during or after endocrine therapy is detected. An antibody that specifically recognizes GDF15 propeptide is included in the CRPC detection reagent.
    Type: Application
    Filed: February 23, 2017
    Publication date: June 24, 2021
    Applicants: PUBLIC UNIVERSITY CORPORATION YOKOHAMA CITY UNIVERSITY, TOSOH CORPORATION
    Inventors: Noriaki ARAKAWA, Hisashi HIRANO, Hiroji UEMURA, Yusuke ITO, Shohei MYOBA, Norihisa OHTAKE
  • Anticancer agents
    Patent number: 7812044
    Abstract: Remedies/preventives for hormone-independent cancer, hormone-independent cancer cell proliferation inhibitors, apoptosis inducers for cancer cells, etc. each containing a compound having an angiotensin II antagonism, its prodrug or a salt thereof. Thus, excellent anticancer agents are provided.
    Type: Grant
    Filed: November 12, 2002
    Date of Patent: October 12, 2010
    Assignee: Takeda Pharmaceutical Company Limited
    Inventors: Yoshinobu Kubota, Hiroji Uemura, Noboru Nakaigawa, Kenichiro Naito
  • Remedies for prostatic hypertrophy
    Publication number: 20070197562
    Abstract: A treatment and/or preventive agent for prostatic hypertrophy includes a compound having an antagonistic effect to an angiotensin II receptor, or a pharmaceutically acceptable salt or a prodrug thereof, as an active ingredient, wherein said compound having an antagonistic effect to an angiotensin II receptor is one or more compounds selected from the group consisting of losartan, potassium losartan, candesartan, candesartan cilexetil, balsartan, eprosartan, zolasartan, telmisartan, irbesartan, tasosartan, olmesartan medoxomil, and olmesartan.
    Type: Application
    Filed: March 9, 2005
    Publication date: August 23, 2007
    Applicant: Yokohama TLO Company, Ltd.
    Inventors: Yoshinobu Kubota, Hiroji Uemura
  • Anticancer agents
    Publication number: 20050119323
    Abstract: Remedies/preventives for hormone-independent cancer, hormone-independent cancer cell proliferation inhibitors, apoptosis inducers for cancer cells, etc. each containing a compound having an angiotensin II antagonism, its prodrug or a salt thereof. Thus, excellent anticancer agents are provided.
    Type: Application
    Filed: November 12, 2002
    Publication date: June 2, 2005
    Inventors: Yoshinobu Kubota, Hiroji Uemura, Noboru Nakaigawa, Kenichiro Naito